|
1
|
Zeng X, Zhang Y, Yang L, Xu H, Zhang T, An
R and Zhu K: Association between RAD51 135 G/C polymorphism and
risk of 3 common gynecological cancers: A meta-analysis. Medicine
(Baltimore). 97:e112512018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodon J, Dienstmann R, Serra V and
Tabernero J: Development of PI3K inhibitors: Lessons learned from
early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barra F, Evangelisti G, Ferro Desideri L,
Di Domenico S, Ferraioli D, Vellone VG, De Cian F and Ferrero S:
Investigational PI3K/AKT/mTOR inhibitors in development for
endometrial cancer. Expert Opin Investig Drugs. 28:131–142. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu R, Yang Z, Xu G and Yu S: miR-338
modulates proliferation and autophagy by PI3K/AKT/mTOR signaling
pathway in cervical cancer. Biomed Pharmacother. 105:633–644. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang X, Zhou Y and Gu YE: Tanshinone IIA
induces apoptosis of ovarian cancer cells in vitro and in vivo
through attenuation of PI3K/AKT/JNK signaling pathways. Oncol Lett.
17:1896–1902. 2019.PubMed/NCBI
|
|
6
|
Fruman DA, Meyers RE and Cantley LC:
Phosphoinositide kinases. Annu Rev Biochem. 67:481–507. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vanhaesebroeck B, Guillermet-Guibert J,
Graupera M and Bilanges B: The emerging mechanisms of
isoform-specific PI3K signalling. Nat Rev Mol Cell Biol.
11:329–341. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo H, German P, Bai S, Barnes S, Guo W,
Qi X, Lou H, Liang J, Jonasch E, Mills GB and Ding Z: The PI3K/AKT
pathway and renal cell carcinoma. J Genet Genomicsbao. 42:343–353.
2015. View Article : Google Scholar
|
|
9
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Auger KR, Serunian LA, Soltoff SP, Libby P
and Cantley LC: PDGF-dependent tyrosine phosphorylation stimulates
production of novel polyphosphoinositides in intact cells. Cell.
57:167–175. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ruderman NB, Kapeller R, White MF and
Cantley LC: Activation of phosphatidylinositol 3-kinase by insulin.
Proc Natl Acad Sci USA. 87:1411–1415. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Samuels Y and Ericson K: Oncogenic PI3K
and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vadas O, Burke JE, Zhang X, Berndt A and
Williams RL: Structural basis for activation and inhibition of
class I phosphoinositide 3-kinases. Sci Signal. 4:re22011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dbouk HA, Khalil BD, Wu H, Shymanets A,
Nurnberg B and Backer JM: Characterization of a tumor-associated
activating mutation of the p110β PI 3-kinase. PLoS One.
8:e638332013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Vadas O, Perisic O, Anderson KE,
Clark J, Hawkins PT, Stephens LR and Williams RL: Structure of
lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated
inhibitory mechanism. Mol Cell. 41:567–578. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jaiswal BS, Janakiraman V, Kljavin NM,
Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring
P, et al: Somatic mutations in p85alpha promote tumorigenesis
through class IA PI3K activation. Cancer Cell. 16:463–474. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheung LW, Hennessy BT, Li J, Yu S, Myers
AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, et al:
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer
elucidates a novel mechanism for regulation of PTEN protein
stability. Cancer Discov. 1:170–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun M, Hillmann P, Hofmann BT, Hart JR and
Vogt PK: Cancer-derived mutations in the regulatory subunit
p85alpha of phosphoinositide 3-kinase function through the
catalytic subunit p110alpha. Proc Natl Acad Sci USA.
107:15547–15552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Graupera M, Guillermet-Guibert J, Foukas
LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J,
Cutillas PR, et al: Angiogenesis selectively requires the p110alpha
isoform of PI3K to control endothelial cell migration. Nature.
453:662–666. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Graupera M and Potente M: Regulation of
angiogenesis by PI3K signaling networks. Exp Cell Res.
319:1348–1355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirsch E, Ciraolo E, Franco I, Ghigo A and
Martini M: PI3K in cancer-stroma interactions: Bad in seed and ugly
in soil. Oncogene. 33:3083–3090. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kinross KM, Montgomery KG, Kleinschmidt M,
Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis
T, et al: An activating Pik3ca mutation coupled with Pten loss is
sufficient to initiate ovarian tumorigenesis in mice. J Clin
Invest. 122:553–557. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Toulany M, Maier J, Iida M, Rebholz S,
Holler M, Grottke A, Jüker M, Wheeler DL, Rothbauer U and Rodemann
HP: Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs
stimulate proliferation and post-irradiation cell survival of
K-RAS-mutated cancer cells. Cell Death Discov. 3:170722017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tokunaga E, Oki E, Egashira A, Sadanaga N,
Morita M, Kakeji Y and Maehara Y: Deregulation of the Akt pathway
in human cancer. Curr Cancer Drug Targets. 8:27–36. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Manning BD and Toker A: AKT/PKB signaling:
Navigating the network. Cell. 169:381–405. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alessi DR, James SR, Downes CP, Holmes AB,
Gaffney PR, Reese CB and Cohen P: Characterization of a
3-phosphoinositide-dependent protein kinase which phosphorylates
and activates protein kinase Balpha. Curr Biol. 7:261–269. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Andjelković M, Alessi DR, Meier R,
Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM and
Hemmings BA: Role of translocation in the activation and function
of protein kinase B. J Biol Chem. 272:31515–31524. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Girardi C, James P, Zanin S, Pinna LA and
Ruzzene M: Differential phosphorylation of Akt1 and Akt2 by protein
kinase CK2 may account for isoform specific functions. Biochim
Biophys Acta. 1843:1865–1874. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wong KK, Engelman JA and Cantley LC:
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet
Dev. 20:87–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carpten JD, Faber AL, Horn C, Donoho GP,
Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage
S, et al: A transforming mutation in the pleckstrin homology domain
of AKT1 in cancer. Nature. 448:439–444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mazloumi Gavgani F, Smith Arnesen V,
Jacobsen RG, Krakstad C, Hoivik EA and Lewis AE: Class I
phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β isoforms in
endometrial cancer. Int J Mol Sci. 19(pii): E39312018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Prat J, Gallardo A, Cuatrecasas M and
Catasús L: Endometrial carcinoma: Pathology and genetics.
Pathology. 39:72–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee TY, Martinez-Outschoorn UE, Schilder
RJ, Kim CH, Richard SD, Rosenblum NG and Johnson JM: Metformin as a
therapeutic target in endometrial cancers. Front Oncol. 8:3412018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hua L, Zhang L, Zhang X and Cui Z:
PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial
cancer cells by inhibition of autophagy. Onco Targets Ther.
10:2865–2871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lu KH, Wu W, Dave B, Slomovitz BM, Burke
TW, Munsell MF, Broaddus RR and Walker CL: Loss of tuberous
sclerosis complex-2 function and activation of mammalian target of
rapamycin signaling in endometrial carcinoma. Clin Cancer Res.
14:2543–2550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shen Q, Stanton ML, Feng W, Rodriguez ME,
Ramondetta L, Chen L, Brown RE and Duan X: Morphoproteomic analysis
reveals an overexpressed and constitutively activated phospholipase
D1-mTORC2 pathway in endometrial carcinoma. Int J Clin Exp Pathol.
4:13–21. 2010.PubMed/NCBI
|
|
41
|
Cancer Genome Atlas Research Network, ;
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shi B, Wang Y, Zhao R, Long X, Deng W and
Wang Z: Bone marrow mesenchymal stem cell-derived exosomal miR-21
protects C-kit+ cardiac stem cells from oxidative injury through
the PTEN/PI3K/Akt axis. PLoS One. 13:e01916162018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pavlidou A and Vlahos NF: Molecular
alterations of PI3K/Akt/mTOR pathway: A therapeutic target in
endometrial cancer. ScientificWorldJournal. 2014:7097362014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sun H, Enomoto T, Fujita M, Wada H,
Yoshino K, Ozaki K, Nakamura T and Murata Y: Mutational analysis of
the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin
Pathol. 115:32–38. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kanamori Y, Kigawa J, Itamochi H, Shimada
M, Takahashi M, Kamazawa S, Sato S, Akeshima R and Terakawa N:
Correlation between loss of PTEN expression and Akt phosphorylation
in endometrial carcinoma. Clin Cancer Res. 7:892–895.
2001.PubMed/NCBI
|
|
46
|
Kong D, Suzuki A, Zou TT, Sakurada A, Kemp
LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, et al:
PTEN1 is frequently mutated in primary endometrial carcinomas. Nat
Genet. 17:143–144. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Quddus MR, Ologun BA, Sung CJ, Steinhoff
MM and Lawrence WD: Utility of PTEN expression of endometrial
‘surface epithelial changes’ and underlying atypical endometrial
hyperplasia. Int J Gynecol Pathol. 28:471–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mutter GL: Pten, a protean tumor
suppressor. Am J Pathol. 158:1895–1898. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bansal N, Yendluri V and Wenham RM: The
molecular biology of endometrial cancers and the implications for
pathogenesis, classification, and targeted therapies. Cancer
Control. 16:8–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bertelsen BI, Steine SJ, Sandvei R, Molven
A and Laerum OD: Molecular analysis of the PI3K-AKT pathway in
uterine cervical neoplasia: Frequent PIK3CA amplification and AKT
phosphorylation. Int J Cancer. 118:1877–1883. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Oh KJ, Kalinina A, Park NH and Bagchi S:
Deregulation of eIF4E: 4E-BP1 in differentiated human
papillomavirus-containing cells leads to high levels of expression
of the E7 oncoprotein. J Virol. 80:7079–7088. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Schwarz JK, Payton JE, Rashmi R, Xiang T,
Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS and
Grigsby PW: Pathway-specific analysis of gene expression data
identifies the PI3K/Akt pathway as a novel therapeutic target in
cervical cancer. Clin Cancer Res. 18:1464–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rashmi R, DeSelm C, Helms C, Bowcock A,
Rogers BE, Rader JL, Grigsby PW and Schwarz JK: AKT inhibitors
promote cell death in cervical cancer through disruption of mTOR
signaling and glucose uptake. PLoS One. 9:e929482014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Isakoff SJ, Engelman JA, Irie HY, Luo J,
Brachmann SM, Pearline RV, Cantley LC and Brugge JS: Breast
cancer-associated PIK3CA mutations are oncogenic in mammary
epithelial cells. Cancer Res. 65:10992–11000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bader AG, Kang S and Vogt PK:
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc
Natl Acad Sci USA. 103:1475–1479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhao JJ, Liu Z, Wang L, Shin E, Loda MF
and Roberts TM: The oncogenic properties of mutant p110alpha and
p110beta phosphatidylinositol 3-kinases in human mammary epithelial
cells. Proc Natl Acad Sci USA. 102:18443–18448. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gymnopoulos M, Elsliger MA and Vogt PK:
Rare cancer-specific mutations in PIK3CA show gain of function.
Proc Natl Acad Sci USA. 104:5569–5574. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ocana A, Vera-Badillo F, Al-Mubarak M,
Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD,
Seruga B, Pandiella A and Amir E: Activation of the PI3K/mTOR/AKT
pathway and survival in solid tumors: Systematic review and
meta-analysis. PLoS One. 9:e952192014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Grigsby P, Elhammali A, Ruiz F, Markovina
S, McLellan MD, Miller CA, Chundury A, Ta NL, Rashmi R, Pfeifer JD,
et al: Clinical outcomes and differential effects of PI3K pathway
mutation in obese versus non-obese patients with cervical cancer.
Oncotarget. 9:4061–4073. 2017.PubMed/NCBI
|
|
60
|
Bosch FX, Lorincz A, Muñoz N, Meijer CJ
and Shah KV: The causal relation between human papillomavirus and
cervical cancer. J Clin Pathol. 55:244–265. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Eskander RN and Tewari KS: Exploiting the
therapeutic potential of the PI3K-AKT-mTOR pathway in enriched
populations of gynecologic malignancies. Expert Rev Clin Pharmacol.
7:847–858. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ko J, Lee YH, Hwang SY, Lee YS, Shin SM,
Hwang JH, Kim J, Kim YW, Jang SW, Ryoo ZY, et al: Identification
and differential expression of novel human cervical cancer oncogene
HCCR-2 in human cancers and its involvement in p53 stabilization.
Oncogene. 22:4679–4689. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cho GW, Shin SM, Namkoong H, Kim HK, Ha
SA, Hur SY, Kim TE, Chai YG and Kim JW: The phosphatidylinositol
3-kinase/Akt pathway regulates the HCCR-1 oncogene expression.
Gene. 384:18–26. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gui T and Shen K: The epidermal growth
factor receptor as a therapeutic target in epithelial ovarian
cancer. Cancer Epidemiol. 36:490–496. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Levine DA, Bogomolniy F, Yee CJ, Lash A,
Barakat RR, Borgen PI and Boyd J: Frequent mutation of the PIK3CA
gene in ovarian and breast cancers. Clin Cancer Res. 11:2875–2878.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Andorfer P, Heuwieser A, Heinzel A, Lukas
A, Mayer B and Perco P: Vascular endothelial growth factor A as
predictive marker for mTOR inhibition in relapsing high-grade
serous ovarian cancer. BMC Syst Biol. 10:332016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cheaib B, Auguste A and Leary A: The
PI3K/Akt/mTOR pathway in ovarian cancer: Therapeutic opportunities
and challenges. Chin J Cancer. 34:4–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Mabuchi S, Kawase C, Altomare DA,
Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M,
Klein-Szanto AJ, Schilder RJ, et al: mTOR is a promising
therapeutic target both in cisplatin-sensitive and
cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer
Res. 15:5404–5413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Di Nicolantonio F, Arena S, Tabernero J,
Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin
D, Mazzucchelli L, et al: Deregulation of the PI3K and KRAS
signaling pathways in human cancer cells determines their response
to everolimus. J Clin Invest. 120:2858–2866. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Altomare DA, Hui QW, Skele KL, De Rienzo
A, Klein-Szanto AJ, Godwin AK and Testa JR: AKT and mTOR
phosphorylation is frequently detected in ovarian cancer and can be
targeted to disrupt ovarian tumor cell growth. Oncogene.
23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Borman SM, Christian PJ, Sipes IG and
Hoyer PB: Ovotoxicity in female Fischer rats and B6 mice induced by
low-dose exposure to three polycyclic aromatic hydrocarbons:
Comparison through calculation of an ovotoxic index. Toxicol Appl
Pharmacol. 167:191–198. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sobinoff AP, Nixon B, Roman SD and
McLaughlin EA: Staying alive: PI3K pathway promotes primordial
follicle activation and survival in response to 3MC-induced
ovotoxicity. Toxicol Sci. 128:258–271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Dobbin ZC and Landen CN: The importance of
the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int
J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Cho D: Novel targeting of
phosphatidylinositol 3-kinase and mammalian target of rapamycin in
renal cell carcinoma. Cancer J. 19:311–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
O'Reilly KE, Rojo F, She QB, Solit D,
Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al:
mTOR inhibition induces upstream receptor tyrosine kinase signaling
and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Figlin RA, Kaufmann I and Brechbiel J:
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New
strategies for overcoming resistance to VEGFR and mTORC1
inhibitors. Int J Cancer. 133:788–796. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Dillon RL, Marcotte R, Hennessy BT,
Woodgett JR, Mills GB and Muller WJ: Akt1 and akt2 play distinct
roles in the initiation and metastatic phases of mammary tumor
progression. Cancer Res. 69:5057–5064. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Endersby R, Zhu X, Hay N, Ellison DW and
Baker SJ: Nonredundant functions for Akt isoforms in astrocyte
growth and gliomagenesis in an orthotopic transplantation model.
Cancer Res. 71:4106–4116. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Behbakht K, Sill MW, Darcy KM, Rubin SC,
Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK and Alpaugh
RK: Phase II trial of the mTOR inhibitor, temsirolimus and
evaluation of circulating tumor cells and tumor biomarkers in
persistent and recurrent epithelial ovarian and primary peritoneal
malignancies: A gynecologic oncology group study. Gynecol Oncol.
123:19–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Takano M, Kikuchi Y, Kudoh K, Goto T,
Furuya K, Kikuchi R, Kita T, Fujiwara K, Shiozawa T and Aoki D:
Weekly administration of temsirolimus for heavily pretreated
patients with clear cell carcinoma of the ovary: A report of six
cases. Int J Clin Oncol. 16:605–609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pétignylechartier C, Duboc C, Jebahi A,
Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L and
Villedieu M: The mTORC1/2 Inhibitor AZD8055 strengthens the
efficiency of the mek inhibitor trametinib to reduce the Mcl-1/[Bim
and Puma] ratio and to sensitize ovarian carcinoma cells to
ABT-737. Mol Cancer Ther. 16:102–115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Itamochi H, Oishi T, Oumi N, Takeuchi S,
Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K,
et al: Whole-genome sequencing revealed novel prognostic biomarkers
and promising targets for therapy of ovarian clear cell carcinoma.
Br J Cancer. 117:717–724. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Sahoo SS, Lombard JM, Ius Y, O'Sullivan R,
Wood LG, Nahar P, Jaaback K and Tanwar PS: Adipose-Derived
VEGF-mTOR signaling promotes endometrial hyperplasia and cancer:
Implications for obese women. Mol Cancer Res. 16:309–321. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Philip CA, Laskov I, Beauchamp MC, Marques
M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH and
Yasmeen A: Inhibition of PI3K-AKT-mTOR pathway sensitizes
endometrial cancer cell lines to PARP inhibitors. BMC Cancer.
17:6382017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Han C, Altwerger G, Menderes G, Haines K,
Feinberg J, Lopez S, Manzano A, Varughese J and Santin AD: Novel
targeted therapies in ovarian and uterine carcinosarcomas. Discov
Med. 25:309–319. 2018.PubMed/NCBI
|
|
91
|
Tamura R, Yoshihara K, Saito T, Ishimura
R, Martínez- Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K,
Suda K, et al: Novel therapeutic strategy for cervical cancer
harboring FGFR3-TACC3 fusions. Oncogenesis. 7:42018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Carneiro BA, Elvin JA, Kamath SD, Ali SM,
Paintal AS, Restrepo A, Berry E, Giles FJ and Johnson ML:
FGFR3-TACC3: A novel gene fusion in cervical cancer. Gynecol Oncol
Rep. 13:53–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Bian X, Gao J, Luo F, Rui C, Zheng T, Wang
D, Wang Y, Roberts TM, Liu P, Zhao JJ and Cheng H: PTEN deficiency
sensitizes endometrioid endometrial cancer to compound PARP-PI3K
inhibition but not PARP inhibition as monotherapy. Oncogene.
37:341–351. 2018. View Article : Google Scholar : PubMed/NCBI
|
